دورية أكاديمية
أعرض في EDS

The Marine Natural Compound Dragmacidin D Selectively Induces Apoptosis in Triple-Negative Breast Cancer Spheroids.

التفاصيل البيبلوغرافية
العنوان: The Marine Natural Compound Dragmacidin D Selectively Induces Apoptosis in Triple-Negative Breast Cancer Spheroids.
المؤلفون: Guzmán EA; Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute, Florida Atlantic University, 5600 US 1 North, Fort Pierce, FL 34946, USA., Peterson TA; Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute, Florida Atlantic University, 5600 US 1 North, Fort Pierce, FL 34946, USA., Wright AE; Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute, Florida Atlantic University, 5600 US 1 North, Fort Pierce, FL 34946, USA.
المصدر: Marine drugs [Mar Drugs] 2023 Dec 15; Vol. 21 (12). Date of Electronic Publication: 2023 Dec 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101213729 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-3397 (Electronic) Linking ISSN: 16603397 NLM ISO Abbreviation: Mar Drugs Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2003]-
مواضيع طبية MeSH: Triple Negative Breast Neoplasms*/drug therapy, Humans ; Cell Proliferation ; Cell Line, Tumor ; Apoptosis
مستخلص: Cancer cells grown in 3D spheroid cultures are considered more predictive for clinical efficacy. The marine natural product dragmacidin D induces apoptosis in MDA-MB-231 and MDA-MB-468 triple-negative breast cancer (TNBC) spheroids within 24 h of treatment while showing no cytotoxicity against the same cells grown in monolayers and treated for 72 h. The IC 50 for cytotoxicity based on caspase 3/7 cleavage in the spheroid assay was 8 ± 1 µM in MDA-MB-231 cells and 16 ± 0.6 µM in MDA-MB-468 cells at 24 h. No cytotoxicity was seen at all in 2D, even at the highest concentration tested. Thus, the IC 50 for cytotoxicity in the MTT assay (2D) in these cells was found to be >75 µM at 72 h. Dragmacidin D exhibited synergy when used in conjunction with paclitaxel, a current treatment for TNBC. Studies into the signaling changes using a reverse-phase protein array showed that treatment with dragmacidin D caused significant decreases in histones. Differential protein expression was used to hypothesize that its potential mechanism of action involves acting as a protein synthesis inhibitor or a ribonucleotide reductase inhibitor. Further testing is necessary to validate this hypothesis. Dragmacidin D also caused a slight decrease in an invasion assay in the MDA-MB-231 cells, although this failed to be statistically significant. Dragmacidin D shows intriguing selectivity for spheroids and has the potential to be a treatment option for triple-negative breast cancer, which merits further research into understanding this activity.
References: Biochem Biophys Res Commun. 2020 Dec 10;533(3):268-274. (PMID: 32958246)
RNA Biol. 2017 Mar 4;14(3):281-286. (PMID: 27211514)
Drug Des Devel Ther. 2015 Aug 05;9:4303-18. (PMID: 26273192)
Cancer Res. 2000 Aug 1;60(15):4152-60. (PMID: 10945623)
Cell. 2017 Nov 30;171(6):1437-1452.e17. (PMID: 29195078)
J Nutr. 2008 Jan;138(1):17-23. (PMID: 18156398)
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243)
Bioengineered. 2021 Dec;12(2):12940-12953. (PMID: 34847838)
Invest New Drugs. 2015 Feb;33(1):86-94. (PMID: 25416019)
Int Rev Cell Mol Biol. 2010;279:1-32. (PMID: 20797675)
J Nat Prod. 1998 May;61(5):660-2. (PMID: 9599272)
Planta Med. 2016 Nov;82(16):1389-1394. (PMID: 27542176)
Mol Cancer Res. 2011 Dec;9(12):1573-86. (PMID: 21970856)
J Biomed Sci. 2015 Jul 04;22:48. (PMID: 26141684)
Int J Oncol. 2007 Dec;31(6):1403-13. (PMID: 17982667)
Transl Oncol. 2022 Jan;15(1):101272. (PMID: 34823094)
Antibiotics (Basel). 2023 Jun 06;12(6):. (PMID: 37370336)
J Cell Biochem. 2014 Nov;115(11):2022-32. (PMID: 24963595)
J Cell Sci. 2017 Jan 1;130(1):203-218. (PMID: 27663511)
Cancer Res. 2010 Sep 1;70(17):6704-14. (PMID: 20643779)
Mini Rev Med Chem. 2009 Jun;9(7):805-12. (PMID: 19519505)
J Hematol Oncol. 2018 May 10;11(1):64. (PMID: 29747682)
J Med Chem. 2002 Mar 14;45(6):1151-75. (PMID: 11881984)
Endocrinology. 2013 Mar;154(3):993-1007. (PMID: 23384835)
Transl Oncol. 2020 Jun;13(6):100775. (PMID: 32408199)
Mar Drugs. 2021 Apr 28;19(5):. (PMID: 33924764)
Assay Drug Dev Technol. 2014 May;12(4):207-18. (PMID: 24831787)
Cancer Res. 2010 Jan 1;70(1):288-98. (PMID: 20028854)
Int J Prev Med. 2013 Nov;4(11):1231-5. (PMID: 24404355)
Br J Cancer. 2013 Oct 1;109(7):1876-85. (PMID: 24008666)
Br J Pharmacol. 1995 Oct;116(4):2315-21. (PMID: 8564266)
Cell Death Differ. 1999 Feb;6(2):99-104. (PMID: 10200555)
Cell Death Differ. 2010 Mar;17(3):381-97. (PMID: 20019744)
Nat Prod Bioprospect. 2023 Aug 29;13(1):27. (PMID: 37640882)
Bull Cancer. 1995 Dec;82(12):987-95. (PMID: 8745664)
Cell Prolif. 2018 Dec;51(6):e12518. (PMID: 30152053)
J Vis Exp. 2015 May 01;(99):e52686. (PMID: 25993495)
Oncol Rep. 2019 Nov;42(5):1735-1744. (PMID: 31436297)
Clin Cancer Res. 2015 Sep 1;21(17):3813-4. (PMID: 26330504)
Can J Physiol Pharmacol. 2022 Jul 1;100(7):612-620. (PMID: 35852219)
N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385)
J Am Chem Soc. 2002 Nov 6;124(44):13179-84. (PMID: 12405846)
Assay Drug Dev Technol. 2015 Sep;13(7):402-14. (PMID: 26317884)
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16686-91. (PMID: 19805358)
Biochem Biophys Res Commun. 2016 Nov 18;480(3):479-485. (PMID: 27773822)
Ann Oncol. 2006 May;17 Suppl 5:v7-12. (PMID: 16807468)
Br J Clin Pharmacol. 2016 Jan;81(1):171-3. (PMID: 26344419)
J Exp Ther Oncol. 2016 Nov;11(4):251-260. (PMID: 27849335)
J Nat Prod. 2005 Jun;68(6):947-50. (PMID: 15974627)
Biol Open. 2013 Feb 14;2(4):379-86. (PMID: 23616922)
Front Cell Dev Biol. 2017 Mar 07;5:18. (PMID: 28326306)
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493. (PMID: 32246720)
Am J Cancer Res. 2019 May 01;9(5):1043-1060. (PMID: 31218111)
Oncogene. 2008 Oct 20;27(48):6245-51. (PMID: 18931691)
BMC Cancer. 2013 Oct 27;13:501. (PMID: 24160245)
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):833-837. (PMID: 29582642)
Mol Cancer Ther. 2006 Oct;5(10):2512-21. (PMID: 17041095)
Front Oncol. 2021 Nov 25;11:753598. (PMID: 34900704)
Br J Pharmacol. 2018 Jan;175(2):232-245. (PMID: 28146604)
J Exp Clin Cancer Res. 2019 Jun 13;38(1):251. (PMID: 31196146)
Mol Cancer Ther. 2008 Jul;7(7):1851-63. (PMID: 18606717)
J Oral Pathol Med. 2022 Jul;51(6):553-562. (PMID: 34661317)
J Biotechnol. 2010 Jul 1;148(1):3-15. (PMID: 20097238)
Crit Rev Oncol Hematol. 2000 May;34(2):127-35. (PMID: 10799837)
Front Cell Dev Biol. 2021 Mar 16;9:641381. (PMID: 33796531)
ChemMedChem. 2010 Nov 8;5(11):1919-26. (PMID: 20839272)
Cancer Cell Int. 2023 Aug 26;23(1):180. (PMID: 37633886)
J Biol Chem. 1967 Jul 10;242(13):3226-33. (PMID: 6027796)
FASEB J. 2019 Aug;33(8):8771-8781. (PMID: 31017817)
Int J Mol Sci. 2021 Dec 21;23(1):. (PMID: 35008473)
معلومات مُعتمدة: P30 CA016672 United States CA NCI NIH HHS; R50 CA221675 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: apoptosis; invasion; marine natural products; reverse-phase protein arrays; spheroids; triple-negative breast cancer
المشرفين على المادة: 0 (dragmacidin D)
تواريخ الأحداث: Date Created: 20231222 Date Completed: 20231225 Latest Revision: 20240218
رمز التحديث: 20240218
مُعرف محوري في PubMed: PMC10871089
DOI: 10.3390/md21120642
PMID: 38132962
قاعدة البيانات: MEDLINE
الوصف
تدمد:1660-3397
DOI:10.3390/md21120642